Skip to content
DNDi Logo
  • DNDi INTERNATIONAL
  • DNDi JAPAN
  • DNDi LATIN AMERICA
  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Menu
  • ABOUT DNDi
    • ABOUT DNDi NORTH AMERICA
    • OUR TEAM
    • BOARD OF DIRECTORS
    • OUR PUBLICATIONS
    • FINANCIALS
    • JOBS
    • Close
  • DISEASES & PROJECTS
  • ADVOCACY
  • MEDIA CENTER
  • DONATE
  • CONTACT
    • Close
  • Home

Media Center

RSS SCIENTIFIC ARTICLES

  • Drug discovery for Chagas disease: A viewpoint
  • Quantifying the infectiousness of post-kala-azar dermal leishmaniasis towards sandflies
  • Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta analysis

RSS PRESS RELEASES

  • Patients treated for visceral leishmaniasis can still transmit the disease even after completing treatment, study shows
  • Nationwide hepatitis C screening campaign initiated by the Malaysian Ministry of Health
  • Chagas Access Programme achieves an increase of 1300% in the number of people screened

RSS NEWS

  • DNDi congratulates the TB Alliance for the FDA approval of a desperately-needed new treatment for drug-resistant forms of tuberculosis
  • DNDi calls for nominations for legal and ethics specialist Board member
  • The disease that strikes back

RSS IN THE MEDIA

  • The Week: “Patients cured of kala-azar can still transmit disease, says study”
  • El Espectador: “Los médicos que quieren controlar en Colombia una enfermedad olvidada por el planeta”
  • Agência Brasil: “Pesquisadores testam novo tratamento contra leishmaniose”

RSS EVENTS

  • DNDi and founders’ symposium
  • 2nd LEAP Scientific Conference
  • 10th NTD NGO Network Conference

RSS Scientific Articles

  • Drug discovery for Chagas disease: A viewpoint
  • Quantifying the infectiousness of post-kala-azar dermal leishmaniasis towards sandflies
  • Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta analysis
  • Hard to study, hard to treat: putting children at the centre of antibiotic research and development

About DNDi

Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected patients.

Subscribe

Sign up for the E-news newsletter! By subscribing, you agree that all info submitted will be processed according to our Privacy Policy. You can unsubscribe any time.

I want to receive

Connect

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
  • Events

DNDi Worldwide

  • DNDi regional offices
  • DNDi Japan のサイトへはこちらから.
  • DNDi Latin America website
  • DNDi North America website

Donate

Support research for neglected disease treatments by making a gift

Authorize.net Seal

Charity Status

GuideStar Gold Participantnewyork-ac-seal-vertical-black-web

Social Mission Ratio

DNDi's social mission ratio

  • PRIVACY POLICY
  • TERMS OF USE
  • ACCEPTABLE USE POLICY
  • COOKIE POLICY
  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser. Read Cookie Policy. Close